Biomea Fusion
Redwood City
About Biomea Fusion
Biomea Fusion is a privately held precision medicine company with a mission to revolutionize drug development to create more effective therapies for cancer patients. Biomea Fusion has a development portfolio that targets specific gene alterations which occur in the DNA of patients that translate into key drivers of tumor growth. It is Biomea’s goal to move these potentially breakthrough medicines swiftly through the development process and deliver highly impactful treatments for patients in need. The lead program targets the protein-to-protein interaction between menin and the MLL complex for the treatment of various tumors.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: $10K – $50K
- Total funding: $271.0M
- Funding stage: IPO
- Last round: Post-IPO Equity (Oct 2025)
- Ticker: nasdaq:BMEA
- Website: biomeafusion.com
- Phone: (650) 980-9099
Industries & Categories
Biotechnology, Life Science, Oncology, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/biomea-fusion-34514 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.